Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)
At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024
Upcoming milestones include completion of enrollment in pivotal Phase 3 clinical trial in NPC1, reporting top line data and preparation for NDA submission
https://finance.yahoo.com/news/cyclo-therapeutics-inc-applied-molecular-120500833.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.